Fexuprazan
- Generic Name
- Fexuprazan
- Indication
用于胃食管反流病（GERD）的治疗。
to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection
Phase 1
Not yet recruiting
- Conditions
- Erosive Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 40
- Registration Number
- NCT06437951
Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids
Phase 4
Not yet recruiting
- Conditions
- Patients on Treatment With Systemic Steroids
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 70
- Registration Number
- NCT05946135
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 9846
- Registration Number
- NCT05886933
- Locations
- 🇰🇷
Co&Ping Otolaryngology Clinic, Busan, Korea, Republic of
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 332
- Registration Number
- NCT05813561
- Locations
- 🇨🇳
Minhu Chen, Guangzhou, Guangdong, China
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- Drug Drug Interaction
- Interventions
- Drug: DWC202201
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 36
- Registration Number
- NCT05812404
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
Active, not recruiting
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 2874
- Registration Number
- NCT05660122
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 10067
- Registration Number
- NCT05614752
- Locations
- 🇰🇷
Jeonbuk National University Hospital, Jeonju, Korea, Republic of
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 36
- Registration Number
- NCT05574374
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 24
- Registration Number
- NCT05304845
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Treatment Effect According to Timing of Administration of DWP14012 40 mg
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 186
- Registration Number
- NCT04888819
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath